2 Stocks to Buy Ahead of ‘Big Pharma’ Buyouts: ORMP, MNKD

According to the American Medical Association (AMA), one in three Americans is overweight.
Moreover, the AMA recently classified obesity as a disease.

This is news that’s bound to trigger a renewed effort in developing treatments for the two most common conditions associated with it:
Diabetes and heart disease.

But for that to happen, we’ll need to see a trend shift.

That’s because Big Pharma’s research and development budgets are anything but robust right now.
(more)
Please share this article